drugset

drugset / Trial / NCT00502385

Phase I AZD2171 in Patients With Relapsed or Refractory AML and Elderly Patients With DeNovo or Secondary AML

NCT00502385 ↗

Phase 1 Completed 54 enrolled AstraZeneca

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The study will be conducted across multiple European centres to assess the safety and tolerability of multiple doses of AZD2171 in patients with AML.

Timeline

Start: 2004-04
Primary completion: —
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cediranib	Small molecule	—	—

Indications